Tag: BIBB.NASDAQ
-
Biogen (BIIB.NASDAQ) and the brain death of big pharma
Ever since the greasy arrogant squirrel-faced grin of Martin Shkreli turned our collective stomach, big pharma has come under fire for their pricing practices. Pharma execs, often paid up to 300 times more than their average employee, shot back that research and development costs were crippling and all that needed to be paid for with…
